ArticleInternational journal of molecular sciences2023
Systemic Inflammation/Nutritional Status Scores Are Prognostic but Not Predictive in Metastatic Non-Small-Cell Lung Cancer Treated with First-Line Immune Checkpoint Inhibitors.
Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Predictability of Neutrophile to Lymphocyte Ratio and Platelet to Lymphocyte Ratio on the Effectiveness of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer patients: A Meta-Analysis.Cancer control : journal of the Moffitt Cancer CenterPooled it
- Perioperative Immunonutrition in Patients Undergoing Lung Cancer Surgery: Current Evidence and Future Perspectives.Nutrients · 2026Review
- Association Between Neutrophil Percentage-to-Albumin Ratio (NPAR) and the Prognosis of Non-Small-Cell Lung Cancer.Cancers · 2026Article
- Dynamic blood-based biomarkers predict early response to ipilimumab and nivolumab in advanced melanoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- A Novel Prognostic Model Based on Prognostic Nutritional Index and Systemic Immune-Inflammation Index for Cancer Patients Treated with Immune Checkpoint Inhibitors.Cancer management and research · 2026Article
- Clinical phenotype identification based on inflammation-nutrition-coagulation biomarkers in advanced non-small cell lung cancer.Frontiers in nutrition · 2026Article
- Prognostic value of combining nutritional inflammatory index trajectories and tumor characteristics in cervical cancer.BMC women's health · 2025Article
- Prognostic relevance of TROP2 expression in patients with non-small cell lung cancer receiving immunotherapy.Scientific reports · 2025Article
- Prognostic biomarkers for extensive-stage small cell lung cancer receiving amrubicin following failure of chemoimmunotherapy: a retrospective cohort study.Translational lung cancer research · 2025Article
- Prognostic factors of liver metastases in extensive-stage small cell lung cancer receiving chemo-immunotherapy.Translational lung cancer research · 2025Article
- Predicting Postoperative Pneumonia in ESCC After Neoadjuvant Chemo-Immunotherapy: Combined Use of ARISCAT Score and Inflammatory Biomarkers.Journal of inflammation research · 2025Article
- Article
- Complete Blood Count-Based Biomarkers as Predictors of Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients with PD-L1 < 50% Treated with First-Line Chemoimmunotherapy.Current oncology (Toronto, Ont.) · 2024Article
- Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non‑small cell lung cancer treated with immunotherapy.Oncology letters · 2024Article
- Identification of C-PLAN index as a novel prognostic predictor for advanced lung cancer patients receiving immune checkpoint inhibitors.Frontiers in oncology · 2024Article
- Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biomarkers of systemic inflammation/nutritional status have been associated with outcomes in advanced-stage non-small-cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). However, most of them were not tested in cohorts of patients treated with ICIs in combination with chemotherapy (CT) (ICI + CT) or with CT alone, making it impossible to discriminate a predictive from a prognostic effect. We conducted a single-center retrospective study to search for associations between various baseline biomarkers/scores that reflected the systemic inflammation/nutritional status (Lung Immune Prognostic Index, Modified Lung Immune Prognostic Index, Scottish Inflammatory Prognostic Score, Advanced Lung Cancer Inflammation Index, EPSILoN, Prognostic Nutritional Index, Systemic Immune-Inflammation Index, Gustave Roussy Immune Score, Royal Marsden Hospital Prognostic Score, Lung Immuno-oncology Prognostic Score 3, Lung Immuno-oncology Prognostic Score 4, score published by Holtzman et al., and Glasgow Prognostic Score) and outcomes in metastatic NSCLC treated in a first-line setting either with ICI in monotherapy (cohort 1;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.